Results with ELIDEL Cream vs. Vehicle Cream at 6-Week Endpoint†6

  • 67% of patients on ELIDEL Cream improved to clear to mild disease vs. 40% of patients on vehicle cream.6
  • Patients applied either ELIDEL Cream or vehicle cream twice daily to 5% to 96% of their BSA for up to 6 weeks.6
  • In clinical studies, skin papillomas or warts were observed in 1% of ELIDEL patients.6
Patients were assessed on the IGA score (0=clear to 5=very severe). Patients were defined as achieving treatment success if facial IGA scores were 0 (completely clear) or 1 (almost clear).
See More


ELIDEL® (pimecrolimus) Cream 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable.



Long-term Safety of Topical Calcineurin Inhibitors Has Not Been Established. Although a causal relationship has not been established, rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including ELIDEL Cream.